Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Trial Comparing Treatment With Melphalan+Prednisolon (MP) With Melphalan+Prednisolon+Thalidomide (MPT) for Previously Untreated Elderly Patients With Multiple Myeloma
Brief Summary: This is a multi-centre Phase III randomized controlled study of patients with multiple myeloma (MM). Eligible patients who are not candidates for transplantation will be randomized to receive eight courses of Melphalan/Prednisolone with or without Thalidomide treatment. Thalidomide will be initiated at the dose of 100 mg/day and maintained at 100 mg/day. The patients will be assessed for any responses at the end of 2nd, 4th, 6th and 8th cycles of treatment. The toxicities will be assessed at monthly intervals. Patients will be assessed for the:

1. Incidence and grade of any toxicity
2. Level of maximum disease response
3. Time to disease progression
4. Time to death


Options:
A: Arm Label: A (Thalidomide & Dexamethasone); Type: EXPERIMENTAL; Interventions: Drug: A (Thalidomide + Dexamethasone) | Arm Label: B (Dexamethasone and placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: B (Placebo + Dexamethasone) | Intervention Type: DRUG; Name: A (Thalidomide + Dexamethasone); Assigned to Arm(s): A (Thalidomide & Dexamethasone) | Intervention Type: DRUG; Name: B (Placebo + Dexamethasone); Assigned to Arm(s): B (Dexamethasone and placebo)
B: Arm Label: Thalidomide; Type: EXPERIMENTAL; Interventions: Drug: Thalidomide, Drug: Melphalan+Prednisolone | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan+Prednisolone | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): Thalidomide | Intervention Type: DRUG; Name: Melphalan+Prednisolone; Assigned to Arm(s): Control, Thalidomide
C: Arm Label: Part 1: VMP+Siltuximab 11 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Siltuximab11 mg/kg, Drug: Velcade (bortezomib), Drug: Melphalan, Drug: Prednisone | Arm Label: Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Siltuximab 8.3 mg/kg or 11 mg/kg, Drug: Velcade (bortezomib), Drug: Melphalan, Drug: Prednisone | Arm Label: Part 2, Arm B: VMP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Velcade (bortezomib), Drug: Melphalan, Drug: Prednisone | Intervention Type: DRUG; Name: Siltuximab11 mg/kg; Assigned to Arm(s): Part 1: VMP+Siltuximab 11 mg/kg | Intervention Type: DRUG; Name: Siltuximab 8.3 mg/kg or 11 mg/kg; Assigned to Arm(s): Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg | Intervention Type: DRUG; Name: Velcade (bortezomib); Assigned to Arm(s): Part 1: VMP+Siltuximab 11 mg/kg | Intervention Type: DRUG; Name: Velcade (bortezomib); Assigned to Arm(s): Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): Part 1: VMP+Siltuximab 11 mg/kg | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Part 1: VMP+Siltuximab 11 mg/kg | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg | Intervention Type: DRUG; Name: Velcade (bortezomib); Assigned to Arm(s): Part 2, Arm B: VMP | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): Part 2, Arm B: VMP | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Part 2, Arm B: VMP
D: Arm Label: MPR+R; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide: Double-blind Induction, Drug: Melphalan, Drug: Prednisone, Drug: Aspirin, Drug: Lenalidomide: Double-blind Maintenance, Drug: Lenalidomide: Open-label | Arm Label: MPR+p; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide: Double-blind Induction, Drug: Melphalan, Drug: Prednisone, Drug: Aspirin, Drug: Placebo, Drug: Lenalidomide: Open-label | Arm Label: MPp+p; Type: OTHER; Interventions: Drug: Melphalan, Drug: Prednisone, Drug: Aspirin, Drug: Placebo, Drug: Lenalidomide: Open-label | Intervention Type: DRUG; Name: Lenalidomide: Double-blind Induction; Assigned to Arm(s): MPR+R, MPR+p | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): MPR+R, MPR+p, MPp+p | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): MPR+R, MPR+p, MPp+p | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): MPR+R, MPR+p, MPp+p | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): MPR+p, MPp+p | Intervention Type: DRUG; Name: Lenalidomide: Double-blind Maintenance; Assigned to Arm(s): MPR+R | Intervention Type: DRUG; Name: Lenalidomide: Open-label; Assigned to Arm(s): MPR+R, MPR+p, MPp+p

Answer: B